Hims & Hers Health stock trades down as sellers push price below long-term averages

Traders Union
All News
Financial News
Hims & Hers Health drops 1.73% today

Highlights

Hims & Hers Health announced a partnership with Novo Nordisk to offer GLP-1 treatments, expanding into high-demand weight management therapies.
The acquisition of Eucalyptus marks Hims & Hers Health's entry into international markets, diversifying its geographic reach and patient base.
HIMS/USD faces mixed technical signals with high intraday selling momentum, consolidating between $30.74 and $35.18 unless $33.9 resistance or key support breaks.

Portfolio expansion and global push amid selling pressure

Hims & Hers Health expanded its direct-to-consumer telehealth platform by introducing new GLP-1 treatments via a partnership with Novo Nordisk, broadening its portfolio in the high-demand weight management space, according to Foreignpolicyjournal. The expansion is aimed at capturing new patient demand for innovative therapies, which could enhance platform utilization and diversify revenue streams. Additionally, the company announced the acquisition of Eucalyptus, marking its first major move beyond the United States, a step that broadens its operational footprint and opens access to international markets, as reported by Foreignpolicyjournal. Both developments were reported amid broader selling pressure.

Divergent momentum as MACD buy clashes with broader sell signals

On the technical side, HIMS is trading below its MA-20 and MA-200, while holding above the MA-50. The Ichimoku Kijun line at $33.9 is acting as immediate resistance. Oscillators show broad selling pressure: the RSI reads 47.33 (Sell), Stoch RSI, CCI, and BBP are all in oversold or seller-dominated territory, and the ADX flags an ongoing trend. Conversely, MACD signals a strong buy, creating a divergence where intraday negative price action and most momentum indicators suggest weakness, while MACD alone points to potential reversal. The Awesome Oscillator is neutral and provides no confirmation.

Sideways consolidation likely as bullish breakout hinges on resistance

Over the next two to three trading days, HIMS is likely to consolidate within a typical volatility band from $30.74 to $35.18. There is a 55% probability of an upward move, activating a bullish scenario if the price breaks above the $33.9 resistance. In a bearish outcome, a breakdown below support would expose the lower edge of the projected range. The baseline scenario remains a sideways consolidation within these established technical levels.

Viktoras Karapetjanc, expert at Traders Union, believes Hims & Hers Health is making decisive strategic moves with the Novo Nordisk partnership and international expansion through Eucalyptus. He sees current price weakness as driven by broader selling, not by company fundamentals or the news flow. Near-term price action may stay choppy, but macro and sentiment outlooks are constructive if support holds. "If HIMS can break above $33.9 resistance, I expect bullish sentiment to return quickly due to the strength of their recent business developments."

Earlier, analysts noted that Hims & Hers Health showed a cautiously bullish technical outlook, tempered by signs of emerging overbought risk and volatility. With the stock now trading below key moving averages and fresh expansion news in play, traders should monitor for a decisive move above the Ichimoku Kijun line at $33.9, as a breakout could shift sentiment and initiate a new upward phase.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.